secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2025-09-11T23:59:59+00:00
Accession:  0001493152-25-013040
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma to host KOL event Sept 18 for ENV105 Phase 2 interim efficacy data
--------------------------------------------------------------------------------

- Virtual KOL event on Sept 18, 2025, at 5 p.m. ET to discuss interim efficacy results from ENV105 Phase 2 trial in advanced prostate cancer.
- ENV105 is a first-in-class CD105 antagonist; interim safety analysis (July 2025) showed well-tolerated with no dose-limiting toxicities or Grade 3/4 events.
- Speakers include principal investigators Drs. Bhowmick, Swami, Lee, and Posadas.
- ENV105 targets CD105-driven drug resistance in castration-resistant prostate cancer; trial combines ENV105 with apalutamide.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000149315225013040/0001493152-25-013040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000149315225013040/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-013040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer